Results of the Multivariable Analyses
Group . | Parameter . | Favorable . | Leukemia-Free Survival . | Nonleukemic Death . | Relapse . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | RR3-150 . | 95% CI . | P Value . | RR . | 95% CI . | P Value . | RR . | 95% CI . | P Value . |
All patients (n = 174) | Status | Remission | .5 | .3-.7 | .0001 | — | — | NS | .3 | .2-.5 | .0001 |
Cell dose | >3.653-151 | .6 | .5-.9 | .01 | .5 | .3-.8 | .003 | — | — | NS | |
Patient CMV status | Seronegative | .7 | .5-1.0 | .05 | — | — | NS | — | — | NS | |
HLA-matching | Mismatch | — | — | NS | — | — | NS | .5 | .3-.9 | .03 | |
Remission (n = 66) | Cell dose | >3.653-151 | .3 | .2-.6 | .0009 | .2 | .1-.4 | .0001 | — | — | NS |
Relapse (n = 94) | Blasts in PB | None | 2.5 | 1.7-5.0 | .0001 | 3.3 | 1.4-10.0 | .002 | — | — | NS |
Blasts in BM | <30% | — | — | NS | — | — | NS | .4 | .2-.8 | .01 | |
Relapse no. | REL1 + REL2 | — | — | NS | — | — | NS | 2.5 | 1.2-5.0 | .01 |
Group . | Parameter . | Favorable . | Leukemia-Free Survival . | Nonleukemic Death . | Relapse . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | RR3-150 . | 95% CI . | P Value . | RR . | 95% CI . | P Value . | RR . | 95% CI . | P Value . |
All patients (n = 174) | Status | Remission | .5 | .3-.7 | .0001 | — | — | NS | .3 | .2-.5 | .0001 |
Cell dose | >3.653-151 | .6 | .5-.9 | .01 | .5 | .3-.8 | .003 | — | — | NS | |
Patient CMV status | Seronegative | .7 | .5-1.0 | .05 | — | — | NS | — | — | NS | |
HLA-matching | Mismatch | — | — | NS | — | — | NS | .5 | .3-.9 | .03 | |
Remission (n = 66) | Cell dose | >3.653-151 | .3 | .2-.6 | .0009 | .2 | .1-.4 | .0001 | — | — | NS |
Relapse (n = 94) | Blasts in PB | None | 2.5 | 1.7-5.0 | .0001 | 3.3 | 1.4-10.0 | .002 | — | — | NS |
Blasts in BM | <30% | — | — | NS | — | — | NS | .4 | .2-.8 | .01 | |
Relapse no. | REL1 + REL2 | — | — | NS | — | — | NS | 2.5 | 1.2-5.0 | .01 |
Abbreviations: BM, bone marrow; CI, confidence interval; CMV, cytomegalovirus; CR, complete remission; n, number; NS, not significant; PB, peripheral blood; REL1, first relapse; REL2, second relapse; RR, relative risk.
Relative risk refers to treatment failure, relapse or death, adverse feature is considered as RR > 1.
Marrow nucleated cells × 108/kg.